This study investigates pancreatic ductal adenocarcinoma. It involves examining the effects of combining an investigational medication with standard chemotherapy treatments.
The study evaluates the safety and effectiveness of this investigational medication in combination with chemotherapy. It focuses on understanding how well the treatment works and its safety profile.
- Who can participate: Adults 18 years or older with resectable pancreatic ductal adenocarcinoma may join. Participants must have good organ function, no prior PDAC treatment, a surgical consult, and meet specific imaging criteria for resectability.
- Study details: Participants will take Fostamatinib with chemotherapy before and after surgery. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.